Frontlight ResearchEarly access
CompletedNo phase
Study of Safety and Effectiveness of the Boston Orthokeratology Shaping Lens in the Arise Orthokeratology Lens
Key facts
- Who runs it
- Bausch & Lomb Incorporated
- Where
- Bloomfield, Edina, Jacksonville, Kirkland, Nashville, and St Louis, United StatesSee the 6 sites
- Trial code
- Status
- Completed
- People taking part
- 90 people enrolled
- Started
- 11 Jul 2023
- Ended
- 27 Jun 2024
- Type of study
- Interventional
- Treatments tested
- orthokeratology lens
- Record updated
- 24 August 2025
Who can take part
- Age
- 12 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- Be 12 years or older on the date the Informed Consent Form (ICF) is signed and, as subject or parent or legal guardian of a minor subject, have capacity to read, understand and provide written voluntary informed consent on the IRB-approved ICF and provide authorization as appropriate for local privacy regulations
- Be orthokeratology lens naïve
- Spherical refractive error between plano and -5.00D
- Astigmatism no greater than 1.50D
- Corneal topography sagittal height differential of ≥ 30 microns between the two main meridians (flat and steep) at an 8mm chord
- Has keratometric readings from 39.00 to 48.00D
- Has a clear and undistorted Mire Reflex
- Be willing and able to comply with all treatment and follow-up study visits and procedures
- Must be willing to refrain from wearing habitual soft contact lenses during the study period
- Subjects must be correctable through spherocylindrical refraction to 42 letters (0.1 logMAR) or better (distance, high contrast) in each eye
Who cannot take part
- Prior eyelid, strabismus, intraocular, or refractive surgery
- Subjects using any systemic or topical medications that will, in the Investigator's opinion, affect ocular physiology or lens performance
- Subjects participating in any drug or device clinical investigation within 2 weeks prior to entry into this study (Screening Visit) and/or planning to do so during the period of study participation
- Subjects with any systemic disease currently affecting ocular health or in the Investigator's opinion may have an effect on ocular health during the course of the study
- A known allergy to fluorescein, benoxinate, or proparacaine
- A history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, ocular viral or fungal infections or recurrent ocular infections
- Subjects with an active ocular disease or who are using any ocular medication
- Subject is considered by the Investigator, to not be a suitable candidate for participation or it is not in the best interest of the subject to participate in the study
- Subjects who have worn rigid gas permeable (RGP) contact lenses within the last 30 days or who have worn polymethylmethacrylate (PMMA) lenses within the last three months
- Keratoconus or an irregular cornea
- Subjects with any Grade 2 or greater finding during the slit lamp examination. Subjects with corneal infiltrates, of ANY GRADE, are NOT eligible. Refer to Appendix B: Methods of Clinical Evaluation
- Subjects with any "Present" finding during the slit lamp examination that, in the Investigator's judgement, interferes with contact lens wear. Refer to Appendix B: Methods of Clinical evaluation
- Subjects with any scar or neovascularization within the central 6mm of the cornea. Subjects with minor peripheral corneal scarring (that does not extend into the central area), that in the Investigator's judgement, does not interfere with contact lens wear, are eligible for this study
- Subjects who are amblyopic
- Immediate family or close relative is a member of the office staff, including the Investigator(s)
- Females of childbearing potential (those who are not surgically sterilized or postmenopausal) if they meet any one of the following:; They are currently pregnant; They plan to become pregnant during the study; They are breastfeeding
Where in United States
- Birmingham Vision Care P.C.Bloomfield, United States
- Cornea and Contact Lens Institute of MinnesotaEdina, United States
- Levenson Eye AssociatesJacksonville, United States
- Speciality Eyecare GroupKirkland, United States
- Optometric Physicians of Middle TennesseeNashville, United States
- The Koetting AssociatesSt Louis, United States
About the trial
What the trial wants to find out
The objective of this orthokeratology study is to evaluate the safety and effectiveness of the Arise Orthokeratology Lens with non-spherical posterior peripheral curves
The group in the trial
- Safety and effectiveness of the Arise Orthokeratology LensTreatment being tested
Treatment effect of overnight orthokeratology over a 3-month period
Treatment: orthokeratology lens
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Study to Evaluate Safety and Effectiveness of the Boston Orthokeratology (Oprifocon A) Shaping Lens in the Arise Orthokeratology Lens Design With Non-spherical Posterior Peripheral Curves
- Record updated
- 24 August 2025